XML 46 R36.htm IDEA: XBRL DOCUMENT v3.23.2

Segment Information (Tables)

6 Months Ended

Jul. 01, 2023

Segment Reporting [Abstract]

Schedule of Segment Information

The following tables present our segment information for the 13 and 26 weeks ended July 1, 2023 and July 2, 2022 (in $000’s):

			Thirteen Weeks Ended												Twenty-Six Weeks Ended
			July 1, 2023						July 2, 2022						July 1, 2023						July 2, 2022
Revenues
Biotechnology			$	—					$	—					$	—					$	—
Discontinued operations			—						10,538						3,795						19,862
Total Revenues			$	—					$	10,538					$	3,795					$	19,862
Gross profit
Biotechnology			$	—					$	—					$	—					$	—
Discontinued operations			—						1,649						(197)						3,502
Total Gross profit			$	—					$	1,649					$	(197)					$	3,502
Operating income (loss)
Biotechnology			$	(1,060)					$	(658)					$	(2,159)					$	(1,339)
Discontinued operations			—						9,639						14,159						9,229
Total Operating income (loss)			$	(1,060)					$	8,981					$	12,000					$	7,890
Depreciation and amortization
Biotechnology			$	362					$	—					$	726					$	2
Discontinued operations			—						135						96						268
Total Depreciation and amortization			$	362					$	135					$	822					$	270
Interest (income) expense, net
Biotechnology			$	(365)					$	(167)					$	(840)					$	(165)
Discontinued operations			—						807						181						418
Total Interest expense, net			$	(365)					$	640					$	(659)					$	253
Net income (loss) before income taxes
Biotechnology			$	62					$	(227)					$	(827)					$	2,392
Discontinued operations			1						9,105						13,976						7,700
Total Net income before income taxes			$	63					$	8,878					$	13,149					$	10,092

X

- Definition

Tabular disclosure of the profit or loss and total assets for each reportable segment. An entity discloses certain information on each reportable segment if the amounts (a) are included in the measure of segment profit or loss reviewed by the chief operating decision maker or (b) are otherwise regularly provided to the chief operating decision maker, even if not included in that measure of segment profit or loss.

+ References

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Name Accounting Standards Codification
-Topic 350
-SubTopic 20
-Section 50
-Paragraph 1
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482573/350-20-50-1

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 25
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482810/280-10-50-25

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 22
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482810/280-10-50-22

Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 30
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482810/280-10-50-30

+ Details

Name:	us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock
Namespace Prefix:	us-gaap_
Data Type:	dtr-types:textBlockItemType
Balance Type:	na
Period Type:	duration

X

- References

No definition available.

+ Details

Name:	us-gaap_SegmentReportingAbstract
Namespace Prefix:	us-gaap_
Data Type:	xbrli:stringItemType
Balance Type:	na
Period Type:	duration